New targets for an old drug by unknown
227
Molecular Targets
New Targets for an Old Drug
II. Hypoxanthine-Guanine Amidophosphoribosyltransferase 
As a New Pharmacodynamic Target 
of Methotrexate
Jacek J. Slon-Usakiewicz,* Andrew Pasternak, Neil Reid,
and Leticia M.Toledo-Sherman†
Protana Inc., OptiMol Drug Discovery Division,Toronto, ON, Canada
Clinical Proteomics Journal
Copyright © Humana Press Inc.
All rights of any nature whatsoever are reserved.
ISSN 1542-6416/04/01:227–234/$25.00
*Author to whom all correspondence and reprint requests should be addressed: 
Jacek J. Slon-Usakiewicz, Protana Inc., OptiMol Drug Discovery Division, 251 Attwell Drive, 
Toronto, ON, M9W 7H4 Canada. 
E-mail: jslon@protana.com
†Present address: Lymphosign Inc., Markham, ON, Canada
Abstract
Methotrexate has been a clinical agent used
in cancer, immunosuppression, rheumatoid
arthritis, and other highly proliferative diseases
for many years, yet its underlying molecular
mechanism of action in these therapeutic areas is
still unclear. We have previously reported using a
chemical proteomics technique on several other
potential pharmacodynamic targets of methotrex-
ate. Here, using a frontal affinity chromatography
with mass spectrometry detection, we confirm
one of these targets, hypoxanthine-guanine ami-
dophosphoribosyltransferase, as a true binder of
methotrexate with a Kd of 4.2 M. These results
complement and confirm our recent study, but
more importantly, shed light into the mechanism
of action of methotrexate in oncology and other
highly proliferative diseases and may help ex-
plain some unaccounted for effects of this drug.
For example, despite the fact that DNA salvage
pathway enzymes are highly active, methotrexate
can be effective if it only targets enzymes of the
de novo pathway.
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Introduction
One of the most important concerns in drug
discovery and development today is the attrition
of compounds in preclinical or clinical stages.
Many compounds are withdrawn at these stages
because of their failure to show efficacy or toler-
able toxicities (1). Several technologies have
started to emerge that specifically aim to address
the underlying reasons for compound attrition.
Among these, the development of computa-
tional tools to predict the absorption, distribu-
tion, metabolism, and excretion/toxicology
(ADME)/tox behavior of compounds (2) and
the development of chemical genomics and pro-
teomics techniques for understanding a drug’s
mechanisms of action and toxicity are promising
(3). In particular, chemical proteomics, the cap-
turing of a select proteome with a chemical
agent or drug, is poised to have the most impact
in that it directly evaluates drug–protein inter-
actions, thus potentially revealing a drug’s true
mechanism of action. Several chemical pro-
teomics applications have emerged in the recent
past (4,5). In particular, affinity-based methods
that measure the affinity of a drug to specific
proteins in a cell lysate or tissue extract under
approximate physiological conditions have
already yielded key mechanistic answers for
several drugs (6).
Methotrexate is one such drug that, despite its
use for many years as a clinical agent in cancer
(7), immunosuppression (8), rheumatoid arthritis
(9), and other highly proliferative diseases, still
has questionable molecular mechanisms of
action in several of these therapeutic areas, spe-
cially immunosuppression and rheumatoid
arthritis (10). In cancer, the mechanism of action
of methotrexate has been understood as occur-
ring as a result of cytotoxicity originating from
the accumulation of the corresponding polyglu-
tamated methotrexate metabolites in cells (11).
Methotrexate is taken into cells by reduced fo-
late carrier protein, where it is polyglutamated
by folylpolyglutamate synthetase (FPGS). On
polyglutamation, methotrexate binds to dihy-
drofolate reductase (DHFR), its known primary
pharmacodynamic target, interrupting the
conversion of dihydrofolate to the activated
N5,N10-methylene-tetrahydrofolate. N5,N10-
methylene-tetrahydrofolate is the main methy-
lene donor in de novo purine biosynthesis; it
provides the methyl group in the conversion of
deoxyuridine 5’-monophosphate to deoxythymi-
dine-5’-monophosphate for DNA synthesis and
for many transmethylation processes. The polyg-
lutamated metabolite is subject to back glutamyl
hydrolysis by -glutamyl hydroxamate (-GH)
and efflux from cells. Several other clinical
oncology targets are known that are inhibited
by methotrexate or other antifolate com-
pounds, mainly thymidylate synthase (TS) and
glycinamide ribonucleotide transformylase
(GART) (12) and amino-imidazolecarboxamide-
ribonucleotide transformylase (AICARFT) (13).
The main problem with methotrexate and
other classical antimetabolites is that accumu-
lation of polyglutamated metabolites in cells
causes drug resistance. Several mechanisms of
resistance (14), such as defective transport
through cell membranes, amplification of
DHFR, reduced expression of FPGS, and
upregulation of -GH, have been identified as
the underlying basis for the development of
resistance to antifolates. Because of the
increased resistance with current antifolate
drugs, there is a need for new antifolate tar-
gets. The development of clinical diagnostic
markers for antifolate drug resistant tumors
would also be beneficial in deciding which
therapies to choose for those tumors. Of equal
importance to clinical applications is the
understanding of the molecular mechanism of
action and toxicity of existing and emerging
antifolate therapeutics.
We have recently reported on methotrexate’s
potential pharmacodynamic target profile (15).
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Using methotrexate, tethered to an agarose
solid support in a manner consistent with
binding DHFR (Fig. 1), the three known antifo-
late targets in the clinic, DHFR, GART, and TS,
and 19 other proteins were recovered in a
single affinity-capture experiment when the
probe was exposed to a cell lysate. Conceptu-
ally, proteins can associate with the immobi-
lized ligand either through a direct binding
interaction or by an association with a direct
binding protein. Using the protein-ligand
docking algorithm Gold (16) in an inverse
docking procedure (17), the proteins were cat-
egorized as direct targets or indirect binders of
methotrexate. In this inverse docking proce-
dure, the methotrexate ligand was docked
against the crystal structure of all but one of
the recovered proteins, and the proposed dock-
ing poses were scored by a consensus scoring
technique. Depending on the proposed binding
mode and binding energy score, we catego-
rized them as direct targets of methotrexate or
indirect interactors that most likely were recov-
ered by a secondary interaction with a direct
target. Specifically, if the proposed binding mode
was similar to that observed for the methotrex-
ate-DHFR complex and the -carboxylate pro-
truded out of the cavity, consistent with
binding to the affinity probe, and the binding
energy score was low, the protein was consid-
ered a direct target. For several of the proteins
we recovered and deemed direct binders, there
was also evidence in the literature for direct
inhibition by methotrexate or folate derivatives.
Here we present conclusive evidence for
direct binding by one of these targets, hypo-
xanthine-guanine amidophosphoribosyltrans-
ferase (HGPRT), and discuss the implications
of these findings. Using a frontal affinity chro-
matography technique coupled to mass spec-
troscopy detection (FAC-MS) we immobilized
HGPRT to a solid support and measured its
binding to methotrexate. The principles on
which FAC-MS are based have been previ-
ously published elsewhere (18), but briefly,
this is an assay based on the continuous
infusion of small molecules over a protein
target that has been immobilized onto a solid
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Fig. 1. (A) Crystal structure of methotrexate complexed within the active site of dihydrofolate reductase
showing the -carboxylate protruding out of the cavity. (B) Methotrexate.
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support column followed by MS detection of
the elutents from the column. As ligands flow
through the column, they bind to the target
with differing affinities. As a result, indi-
vidual ligands are retained in the column,
causing an increase in their breakthrough
volume, that is, the effluent volume passing
through the column that allows the output
ligand concentration to equal the input ligand
concentration. The breakthrough volume,
characterized as a sigmoidal front, can read-
ily be detected by MS and corresponds
directly to the time that the front (break-
through time) is observed to pass through
the column. As such, FAC-MS offers a very
convenient way of measuring the relative
binding strengths of ligands for the immobi-
lized target. We also present here FAC-MS as
a complementary method to our affinity-
based chemical proteomics technique. This
technique, amenable to any protein that can
be immobilized onto a column format, repre-
sents a tool for confirming drug–protein inter-





was obtained from Calbiochem (San Diego,
CA). CBX1000C controlled-pore glass beads
(200/400 m, 972-Å pore size) were purchased
from Millipore (Lincoln Park, NJ). HGPRT




and all other chemicals were purchased from
Sigma-Aldrich (Oakville, ON, Canada).
FAC-MS
CBX1000C (COOH-modified) beads (5 mg)
were activated by reaction with EDAC/NHS
in 0.1 M MES buffer containing 0.5 M NaCl at
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pH 6.4. After 45 min of mixing at room tem-
perature, the beads were centrifuged and the
supernatant was removed. Beads were resus-
pended in 250 L of MES buffer and 100 mg
of protein (in 1× PBS) was added. The mixture
was incubated for 2 h at room temperature
and overnight at 4°C with 360° vertical rota-
tion followed by 1× PBS. After loading immo-
bilized HGPRT, the FAC-MS capillary columns
(250 m id × 2.5 cm) were washed with 50 L
(at 200 L/h) of 1× PBS buffer followed by
50 L of the running buffer (20 mM NH4OAc
containing 1% dimethyl sulfoxide [DMSO]).
The analyte solution contained methotrexate
(1 M) as the indicator and M3 (1 M) as the
void marker in 20 mM NH4OAc containing
1% DMSO. The makeup buffer was 90%
methanol containing 0.1% acetic acid in water.
The flow rates used were 80 L/h for the
makeup buffer and 100 L/h for the FAC-MS
columns. The column was connected to an
AB/Sciex API 3000 triple-quadrupole mass
spectrometer (Concord, ON, Canada) and sy-
ringe pumps (Harvard Biosciences, Holliston,
MA) and was allowed to equilibrate with the
running buffer until the methotrexate (M+H)
signal was stable, then data were acquired.
After 1 min, the system was switched to the
analyte solution and data collection continued
until the methotrexate signal had maximized
for at least 10 min. The column was washed
with running buffer until the methotrexate
signal had reduced to its background level to
regenerate the column. The data were ana-
lyzed using a customized Excel macro to





HGPRT is the most important enzyme of
purine salvage pathway. It catalyzes the salvage
conversion of hypoxanthine and guanine to
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inosine 5’-monophosphate (IMP) and guanine
5’-monophosphate (GMP) respectively, by
facilitating the addition of the bases to the acti-
vated phosphoribosylpyrohosphate (PRPP)
molecule (19). HGPRT had been previously
identified by our earlier affinity-capture exper-
iments from a cell lysate as a potential binder
to methotrexate. Our inverse docking experi-
ments were consistent with direct binding, as
we found several low energy binding modes
for methotrexate showing a good fit in the
HGPRT binding pocket and with the gluta-
mate group protruding out of the cavity, con-
sistent with binding the probe directly. In these
binding modes, methotrexate shows a good
overlap (Fig. 2) with the experimental position
occupied by the hypoxanthine monophosphate
cofactor from the crystal structure complex of
HGPRT with hypoxanthine monophosphate
(pdb code: 1D6N [20]). There is also evidence
from the literature indicating that HGPRT
should be a direct target of methotrexate. For
example, it is known that other enzymes that
bind IMP can also be subject to inhibition by
folates and methotrexate (21). Furthermore, it is
also known from extensive medicinal chemistry
work on antimetabolite drug research that the
pterin group of methotrexate can be replaced
with xanthine and xanthine-like moieties and
vice versa. Examples of this are pemetrexed
(ALIMTA, LY-231514), the classical antimetab-
olite TS inhibitor drug from Lilly (22), and
tomudex (ZD9331), the nonclassical TS inhibi-
tor from AstraZeneca (23).
The activity of salvage enzymes like
HGPRT is higher than the activity of enzymes
Fig. 2. Proposed binding mode for methotrexate in hypoxanthine-guanine amidophosphoribosyltransferase.
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involved in the de novo purine pathways, such
as GART, AICARFT, and DHFR, the known
targets of methotrexate (24). It has been puz-
zling that agents such as methotrexate and
other antimetabolites, believed to act primarily
on de novo enzymes, are effective despite the
presence of highly active salvage enzymes.
This has recently been partly accounted for by
new observations showing that methotrexate
can reduce the activity of HGPRT (25). Other
observations suggest in vivo inhibition of
HGPRT by methotrexate. For example, defi-
ciency in HGPRT is known to result in higher
levels of PRPP and an acceleration of purine
biosynthesis by the de novo pathway (26).
Treatment with methotrexate also produces an
increase in levels of PRPP (27) and this effect
is reversible on treatment with hypoxanthine.
In order to confirm HGPRT as a direct phar-
macodynamic target of methotrexate, we im-
mobilized it on a solid support by covalent
attachment. To evaluate potential binding of
methotrexate, we first examined its MS signal.
A molecular ion (M+H)+ 455.5 corresponding
to the molecular weight of 454.5 showed
strong intensity, good stability, and dynamic
range. Nonspecific interactions of methotrex-
ate were tested with blank columns packed
with nonmodified controlled-pore glass (CBX)
beads and with columns packed with bovine
serum albumin (BSA) immobilized beads 
(Fig. 3). The breakthrough times of methotrex-
ate for both columns was determined to be
minimal (approx 0.2 min), indicating that
methotrexate has very little nonspecific bind-
ing to both CBX beads and to neutral 
protein. These features make methotrexate an
excellent indicator for FAC-MS experiments.
After immobilization of HGPRT onto the
beads, confirmation of FAC-MS activity was
obtained, as shown in Fig. 4, by seeing sig-
nificant binding (delayed breakthrough time
of 56 min compared with the void marker, M3
at 9 min) of methotrexate at a concentration
of 1 M. These data, along with very low non-
specific binding, indicate that methotrexate is
truly binding to HGPRT. Using the direct
method (staircase) (28), we determined (data
not shown) that the Kd of methotrexate for
HGPRT is 4.2 M. We also believe that this
binding would be preserved with HGPRT
derived from mammalian sources.
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Fig. 3. Frontal affinity chromatography-mass spectroscopy (FAC-MS) chromatogram of nonspecific binding of
methotrexate to CBX beads and CBX beds with immobilized bovine serum albumin (thick lines).The thin line
represents the void marker (M3).
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Conclusions
We have recently shown by a chemical pro-
teomics experiment that when methotrexate is
immobilized on a solid support in a manner
compatible with binding its known target
DHFR, and exposed to a cell lysate, many
other proteins associated with de novo and sal-
vage purine biosynthetic pathways are cap-
tured. Three of these, DHFR, GART, and TS,
are already known as pharmacodynamic tar-
gets of this drug or other antimetabolites,
respectively. Using an inverse protein-ligand
docking technique and evidence from the lit-
erature, we had proposed that at least 9 of the
21 identified proteins are potential direct tar-
gets of methotrexate. In the current experi-
ment, we make use of FAC-MS to confirm our
earlier results and provide conclusive evi-
dence for direct binding of methotrexate by
one of these targets, HGPRT. This target binds
methotrexate with a Kd of 4.2 M. Our find-
ings and evidence from the literature indicate
that direct inhibition of HGPRT by methotrex-
ate is at least in part responsible for methotrex-
ate’s efficacy as an anticancer agent and other
highly proliferative diseases.
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